Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

476 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.
Fox LC, Cummins KD, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarer A, Harrup R, Holmes A, Ratnasingam S, Chan KL, Hsu WH, Ashraf A, Putt F, Grigg A. Fox LC, et al. Among authors: forsyth c. Blood Adv. 2017 May 15;1(13):802-811. doi: 10.1182/bloodadvances.2016003889. eCollection 2017 May 23. Blood Adv. 2017. PMID: 29296724 Free PMC article.
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group. Yeung DT, et al. Among authors: forsyth cj. Blood. 2015 Feb 5;125(6):915-23. doi: 10.1182/blood-2014-07-590315. Epub 2014 Dec 17. Blood. 2015. PMID: 25519749 Free PMC article. Clinical Trial.
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
Minson AG, Cummins K, Fox L, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarer A, Harrup R, Holmes A, Ratnasingam S, Chan KL, Hsu WH, Ashraf A, Putt F, Grigg A. Minson AG, et al. Among authors: forsyth c. Blood Adv. 2019 Apr 9;3(7):1084-1091. doi: 10.1182/bloodadvances.2018028035. Blood Adv. 2019. PMID: 30944100 Free PMC article.
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.
Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Doo NW, Keane C, Talaulikar D, Berkahn L, Morgan S, Hamad N, Cochrane T, Johnston AM, Forsyth C, Opat S, Barraclough A, Mutsando H, Ratnasingam S, Giri P, Wood EM, McQuilten ZK, Hawkes EA; Lymphoma and Related Diseases Registry investigators. Nguyen J, et al. Among authors: forsyth c. Eur J Haematol. 2023 Apr;110(4):386-395. doi: 10.1111/ejh.13915. Epub 2022 Dec 28. Eur J Haematol. 2023. PMID: 36539351
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.
Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, Arriola-Martinez L, Pozsgai MJ, McNeely KE, Ha T, Venugopal P, Arts P, King-Smith SL, Cheah J, Armstrong M, Wang P, Bödör C, Cantor AB, Cazzola M, Degelman E, DiNardo CD, Duployez N, Favier R, Fröhling S, Rio-Machin A, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Kim E, Sood R, Hsu AP, Holland SM, Phillips K, Poplawski NK, Babic M, Wei AH, Forsyth C, Mar Fan H, Lewis ID, Cooney J, Susman R, Fox LC, Blombery P, Singhal D, Hiwase D, Phipson B, Schreiber AW, Hahn CN, Scott HS, Liu P, Godley LA, Brown AL; NISC Comparative Sequencing Program. Homan CC, et al. Among authors: forsyth c. Blood Adv. 2023 Oct 24;7(20):6092-6107. doi: 10.1182/bloodadvances.2023010045. Blood Adv. 2023. PMID: 37406166 Free PMC article.
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.
Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong ASM, Shortt J, Chee L, Viiala N, Cunningham I, Ross DM, D'Souza A, Wright M, Harrup R, Forsyth C, Filshie R, Lane S, Browett P, Grove C, Grigg AP, Hughes TP. Yeung DT, et al. Among authors: forsyth c. Blood. 2024 Nov 7;144(19):1993-2001. doi: 10.1182/blood.2024024657. Blood. 2024. PMID: 39102630
476 results